Comparative effectiveness of anti-VEGF agents for diabetic macular edema (Q35056819)

6 August 2017

title

Comparative effectiveness of anti-VEGF agents for diabetic macular edema (English)

1 reference

6 August 2017

Daniel A Ollendorf

1

1 reference

6 August 2017

Jennifer A Colby

series ordinal

2

1 reference

6 August 2017

Steven D Pearson

series ordinal

3

1 reference

6 August 2017

publication date

1 October 2013

1 reference

International Journal of Technology Assessment in Health Care

6 August 2017

published in

1 reference

6 August 2017

volume

29

1 reference

6 August 2017

issue

4

1 reference

6 August 2017

page(s)

392-401

1 reference

Managing diabetic macular edema: The leading cause of diabetes blindness

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0266462313000500

Diabetic retinopathy in a multi-ethnic cohort in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462313000500

Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462313000500

Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462313000500

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462313000500

A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462313000500

US valuation of the EQ-5D health states: development and testing of the D1 valuation model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462313000500

Development of the 25-item National Eye Institute Visual Function Questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462313000500

Visual acuity as an outcome measure in clinical trials of retinal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462313000500

Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462313000500

Direct and indirect costs among employees with diabetic retinopathy in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462313000500

A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462313000500

Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462313000500

The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462313000500

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462313000500

Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462313000500

Targeting the pathophysiology of diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462313000500

Intravitreal avastin: the low cost alternative to lucentis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462313000500

7 January 2021

Relationship between vision impairment and ability to perform activities of daily living

1 reference

https://api.crossref.org/works/10.1017%2FS0266462313000500

7 January 2021

Vision and self-reported mobility performance in patients with low vision

1 reference

https://api.crossref.org/works/10.1017%2FS0266462313000500

7 January 2021

Etiology and natural history of diabetic retinopathy: an overview

1 reference

https://api.crossref.org/works/10.1017%2FS0266462313000500

7 January 2021

Photocoagulation for Diabetic Macular Edema

1 reference

https://api.crossref.org/works/10.1017%2FS0266462313000500

7 January 2021

https://api.crossref.org/works/10.1017%2FS0266462313000500

1 reference

7 January 2021

10.1017/S0266462313000500

Identifiers

DOI

1 reference

6 August 2017

1 reference